NCT01738451 - A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 22, 2013

Primary Completion Date

November 28, 2014

Study Completion Date

November 28, 2014

Conditions

Cancer

Interventions

DRUG

GSK2118436 75 mg

Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.

DRUG

Placebo

Matching placebo capsules will be administered in Part 2 of the study.

Trial Locations (8)

GSK Investigational Site, Melbourne

GSK Investigational Site, Heidelberg

GSK Investigational Site, Nashville

GSK Investigational Site, Memphis

GSK Investigational Site, San Antonio

GSK Investigational Site, Scottsdale

GSK Investigational Site, Salt Lake City

GSK Investigational Site, London